Dr. Reddy's Laboratories' Aurigene Oncology Unit Results From 1st Two Groups Of Phase 1 Clinical Study Of AUR112 Demonstrates Safety, Meaningful Clinical Activity With Objective Responses Observed Across Multiple Lymphoma Subtypes

Benzinga · 3d ago

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).